How to buy CRISPR Therapeutics (CRSP) shares in Australia
Learn how to easily invest in CRISPR Therapeutics shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
CRISPR Therapeutics AG is a biotechnology business with stocks listed in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$58.76 – a decrease of 6.15% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in CRISPR Therapeutics
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for CRISPR Therapeutics. Find the share by name or ticker symbol: CRSP. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CRISPR Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$66.4, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of CRISPR Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of CRISPR Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- CRISPR Therapeutics key stats
- Compare share trading platforms
- Is CRISPR Therapeutics stock a buy or sell?
- CRISPR Therapeutics performance over time
- Are CRISPR Therapeutics shares over-valued?
- CRISPR Therapeutics's financials
- How volatile are CRISPR Therapeutics shares?
- Does CRISPR Therapeutics pay a dividend?
- Have CRISPR Therapeutics shares ever split?
- Other common questions
CRISPR Therapeutics stock price (NASDAQ:CRSP)Use our graph to track the performance of CRSP stocks over time.
CRISPR Therapeutics shares at a glance
|52-week range||US$62.21 - US$191.1|
|50-day moving average||US$76.3982|
|200-day moving average||US$108.2373|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$5.263|
Where to buy CRISPR Therapeutics stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy CRISPR Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
CRISPR Therapeutics price performance over time
|1 month (2021-12-27)||-23.65%|
|3 months (2021-10-28)||-37.49%|
|6 months (2021-07-28)||-50.93%|
|1 year (2021-01-28)||-64.90%|
|2 years (2020-01-28)||6.18%|
|3 years (2019-01-28)||88.51%|
|5 years (2017-01-27)||218.83%|
Is CRISPR Therapeutics under- or over-valued?
Valuing CRISPR Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CRISPR Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CRISPR Therapeutics's P/E ratio
CRISPR Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, CRISPR Therapeutics shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
CRISPR Therapeutics's EBITDA
CRISPR Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$425.7 million (£318 million).
The EBITDA is a measure of a CRISPR Therapeutics's overall financial performance and is widely used to measure a its profitability.
CRISPR Therapeutics financials
|Revenue TTM||US$902.4 million|
|Operating margin TTM||45.6%|
|Gross profit TTM||US$-266,227,000|
|Return on assets TTM||11.94%|
|Return on equity TTM||21.36%|
|Market capitalisation||US$4.8 billion|
TTM: trailing 12 months
CRISPR Therapeutics share dividends
We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.
Have CRISPR Therapeutics's shares ever split?
CRISPR Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before the split, the next day you would own 333333 shares. This wouldn't directly have changed the overall worth of your CRISPR Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for CRISPR Therapeutics shares which in turn could have impacted CRISPR Therapeutics's share price.
CRISPR Therapeutics share price volatility
Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as US$62.21 up to US$191.1. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 2.0471. This would suggest that CRISPR Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CRISPR Therapeutics overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
CRISPR Therapeutics in the news
Better Biotech Stock: CRISPR Therapeutics or Twist Bioscience?
Market Dip? Here's Why This Bargain Biotech Is a Smart Buy Now
Ackman takes a big stake in Netflix, excited about company's long-term prospects
Frequently asked questions
More guides on Finder
Ethereum price plummets as crypto industry’s combined market cap drops by 10% within hours
With the total market cap of the crypto sector dropping by a whopping 10% within the last few hours, it seems as though the coming few days could be highly volatile for ETH.
Back to school laptops: Buying guide
What are the things to watch out for when buying your child's first laptop?
Bitcoin price dips below key level as Russia prepares for a blanket crypto ban
As Russia gets ready to outlaw its local crypto market, BTC could be faced with even greater volatility in the near future.
How to watch UFC 270 Ngannou vs Gane online and start time in Australia
Heavyweight stars Fancis Ngannou and Cyril Gane headline UFC 270.
Why has the Rio Tinto share price dropped today?
Shares in Rio Tinto have climbed more than 15% in the last month.
Today’s ASX top stocks: Stanmore Coal (SMR ↑5.2%), Kelly Partners Group Holdings (KPG ↑3.3%)
Here are the 10 biggest movers on the ASX for Friday 21 January 2022.
Beauty Product of the Week: Gisou Honey Infused Leave-In Conditioner
This leave-in conditioner transformed my unwashed mop into silky locks that would make Rapunzel envious.
Samsung confirms Galaxy S22 Ultra will be a Note phone
Samsung's next flagship S22 phone will be, in its own less than subtle phrasing, "noteworthy".
Top 10 TV shows in Australia this week and where to watch them
A fun superhero series, an epic sci-fi and a dark teen drama are among our top picks this week.
Ask an Expert